Key Highlights

  • Lumos Diagnostics shares traded at $0.067, down 20.24%, during the 27 October 2026 trading session.
  • FebriDx is being ordered at 265 US sites across 29 states as of 11 October 2026.
  • Q1 FY27 total Revenue was US$2.0 million, with cash of US$11.8 million and no debt.

Shares in Lumos Diagnostics Holdings Ltd (ASX:LDX) were trading at $0.067, down 20.24%, during the 27 October 2026 trading session, while the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Lumos Diagnostics is a Melbourne-based developer of rapid point-of-care diagnostic technologies, including FebriDx. On the same day, the company released its Q1 FY27 quarterly activity statement and Appendix 4C.

US Commercial Update (27 October 2026)

In its 27 October 2026 statement, Lumos said 265 healthcare sites across 29 states were actively ordering FebriDx as of 11 October 2026, up from 215 sites on 15 September and 170 on 26 July. Evaluations are under way at 485 sites, up from 405.

Thirteen of the top 100 urgent care groups are in evaluation or live, and a primary care health system with more than 12 locations committed to deploy across all sites. Q1 FY27 revenue was US$2.0 million, with product revenue up 224% and FebriDx sales up 351% excluding a one-time exclusivity fee in the prior period.

Paediatric Study and Cash Position

About 400 patients have been enrolled in the FebriDx paediatric study. The company said total enrolment and bacterial-positive cases were lower than the study plan expected. Three hospital emergency departments are being added in Q2 FY27, and Lumos and BARDA are engaging with the FDA on whether study parameters can be adjusted.

Cash was US$11.8 million at 30 September 2026 and the company is debt-free. Operating cash outflow was US$4.7 million, including US$1.0 million of inventory ahead of the 2026/27 respiratory season.

Sector Context

The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Diagnostics and medical device companies report commercial progress through customer sites, product revenue and clinical study enrolment.

Lumos Diagnostics shares were trading at $0.067, down 20.24%, against a benchmark gain of 0.49%, a gap of 20.73 percentage points. The figures are session data recorded while the market was open and can change before the market finishes trading.

Risks

The paediatric study is enrolling below plan, and the study parameters may require FDA discussion. Operating cash outflow of US$4.7 million for the quarter compares with cash of US$11.8 million.

What Lies Ahead

The update points to additional emergency department sites in Q2 FY27, discussions with BARDA and the FDA, continued site evaluations and the respiratory season ordering pattern.

Final Takeaway

Lumos shares fell during the session on the day of its quarterly update, which reported site growth alongside lower-than-expected paediatric study enrolment.